Mitochondria Day 2020

On the occasion of The World Mitochondrial Disease Week, Abliva held a virtual Mitochondria Day 2020, on 16 September at 2 p.m. – 4 p.m. CEST. The purpose of the day was to increase understanding of the enormous medical need within primary mitochondrial diseases, treatments under development, as well as the growing interest in investments in the area.

The program was designed to be of interest both for those who have a professional interest – in health care, research, or the media – as well as for patients, relatives, and the interested public. The annual Mitochondria Day is part of The World Mitochondrial Disease Week, which runs one week every year in September.


Welcome. Abliva’s CEO Erik Kinnman gives an introduction to the day.

Healthcare perspective: Symptoms, epidemiology, diagnosis, prognosis, and treatment. Karin Naess and Martin Engvall, Karolinska Institutet, Sweden.

The role of patient organizations. Interview with Elja van der Veer, Founder and Chair of International Mito Patients.

What is it like to live with a mitochondrial disease? Interview with Dr. Adrian Horvath who has a daughter with a primary mitochondrial disease.

Short film. Meet the Horvath family.

Q&A with Martin Engvall.

Opportunities in drug development of therapeutics for primary mitochondrial diseases. Magnus Hansson, Chief Medical Officer at Abliva.

Abliva’s ongoing and planned clinical studies in primary mitochondrial diseases. Matilda Hugerth, Director Clinical and Regulatory Affairs at Abliva.

Inside the head of FDA: How does the US Food & Drug Adminstration think about orphan drugs? Frank J. Sasinowski, former Director at the FDA, Consultant specializing in regulatory matters for orphan drugs in the US. 

Why is there an increasing capital markets interest in investing in rare disease projects? Discussion with Roger Franklin – partner Hadean Ventures and board member of Abliva, Annika Espander – CEO of Asperion, and Erik Kinnman – CEO of Abliva.


Summary and closure.